Free shipping on all orders over $ 500

Ro3280

Cat. No. M2983
Ro3280 Structure
Synonym:

Ro5203280

Size Price Availability Quantity
2mg USD 105  USD105 In stock
5mg USD 155  USD155 In stock
10mg USD 220  USD220 In stock
50mg USD 880  USD880 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.

Customer Product Validations & Biological Datas
Source Oncol Rep (2017). Figure 2. Ro3280
Method Western blotting
Cell Lines NB4 cells
Concentrations 200 and 500 nM
Incubation Time 4 h
Results Western blotting showed more LC3-II in NB4 cells treated with RO3280 and BI2536. More LC3-II was observed in the 100-500 nM RO3280 group and in the 200-500 nM BI2536 group
Chemical Information
Molecular Weight 543.61
Formula C27H35F2N7O3
CAS Number 1062243-51-9
Solubility (25°C) DMSO 70 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Mustafa Ergul, et al. RO3280: A Novel PLK1 Inhibitor, Suppressed the Proliferation of MCF-7 Breast Cancer Cells Through the Induction of Cell Cycle Arrest at G2/M Point

[2] Yan-Fang Tao, et al. Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation

[3] Zhe Zhang, et al. Targeted inhibition of Polo-like kinase 1 by a novel small-molecule inhibitor induces mitotic catastrophe and apoptosis in human bladder cancer cells

[4] Na-Na Wang, et al. Molecular targeting of the oncoprotein PLK1 in pediatric acute myeloid leukemia: RO3280, a novel PLK1 inhibitor, induces apoptosis in leukemia cells

[5] Shaoqing Chen, et al. Identification of novel, potent and selective inhibitors of Polo-like kinase 1

Related PLK Products
3MB-PP1

3MB-PP1 is a bulky purine analog and inhibitor of Polo-like kinase 1 (Plk1) that blocks mitotic progression and cytokinesis by targeting Plk1 in cells expressing the analog-sensitive Plk1 allele. 3MB-PP1 also specifically inhibits the activity of Leu93 mutant Zipper-interacting Ssn3 (Cdk8). 3MB-PP1 inhibits the activity of Leu93 mutant Zipper-interacting Ssn3 (Cdk8). In addition, 3MB-PP1 specifically inhibits the activity of analog-sensitive Ssn3 (Cdk8). 3MB-PP1 inhibits the Leu93 mutant Zipper-interacting protein kinase (Leu93-ZIPK; IC50=2 μM). 3MB-PP1 can be used in the mycelium of Candida albicans. 3MB-PP1 can be used in studies related to mycelium formation and cell division in Candida albicans.

CYC-800

CYC-800 is a PLK1 inhibitor that can be used in tumor-related studies.

SOL-686

SOL-686 is a PLK1 inhibitor that can be used in glioma-related studies.

BAL0891

BAL0891 is a potential first-in-class PLK1/TTK inhibitor with antiproliferative activity for studies related to solid tumors.

Plogosertib

Plogosertib is a selective, potent, orally active, ATP-competitive PLK1 inhibitor with an IC50 value of 3 nM.In addition, Plogosertib exhibits antiproliferative and anticancer activity and can be used in a variety of tumor studies.

  Catalog
Abmole Inhibitor Catalog




Keywords: Ro3280, Ro5203280 supplier, PLK, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.